Aljohani S, et al. - Researchers investigated if osteonecrosis of the jaw, reported in relation to denosumab treatment of metastatic bone disease or osteoporosis, is a new osteonecrosis entity in order to recognize its optimal management strategies. Cancer patients displayed denosumab-related osteonecrosis of the jaw (DRONJ) more frequently at extraction and local infection sites. For the management of DRONJ, surgical treatment, particularly fluorescence-guided surgery, seems effective, within the limitation of this study. No effect of prior use of bisphosphonates on severity or on the treatment success rate of DRONJ was suggested.